Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Trial of Biphasic Insulin Aspart 30 in Type 2 Diabetes
NCT01527539Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2001
- Primary completion
- Oct 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Insulin aspart + insulin aspart protamine in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Glycated Hemoglobin A1c. Started Nov 2001; status: completed.
02
Drugs
Insulin aspart + insulin aspart protamine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01527539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01527539.